COMMUNIQUÉS West-GlobeNewswire

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
28/09/2026
Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to a definitive agreement NEW [...]
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
28/09/2026
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 [...]
BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team
28/09/2026
New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray Brands ELLON, Scotland and LONDON, Sept. 28, 2026 (GLOBE NEWSWIRE [...]
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
28/09/2026
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits – Independent Cleveland Clinic cardio-oncology [...]
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
28/09/2026
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: [...]
Pharmazz Completes Enrollment in 160-Patient Phase 4 Trial of Sovateltide in Acute Ischemic Stroke
28/09/2026
Enrollment completed in the double-blind, placebo-controlled Phase 4 study ( NCT05955326 ) of sovateltide (Tycamzzi®), with final study data expected in Q1 2027 Five sovateltide abstracts accepted at World Stroke [...]
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
28/09/2026
- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study - - Patients with stable or increased weight at three months had [...]
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
28/09/2026
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology WALTHAM, Mass., Sept. 28, 2026 ( [...]
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
28/09/2026
BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need Non-dilutive funding for SCY- [...]
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
28/09/2026
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and [...]
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
28/09/2026
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future [...]
Inventiva publie ses résultats financiers non audités du premier semestre 2026 et fait le point sur ses activités
28/09/2026
Trésorerie et équivalents de trésorerie à 166,1 millions d’euros et dépôts à court terme 1 à 67,8 millions d’euros au 30 juin 2026 Horizon de trésorerie inchangé par rapport au 30 juillet 2026 2 Résultats principaux de [...]
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
28/09/2026
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits 1 as of June 30, 2026 Cash runway guidance remains unchanged from July 30, 2026 2 Topline results of the Phase 3 NATiV3 clinical trial [...]
Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7
28/09/2026
September 28, 2026 News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
28/09/2026
COPENHAGEN, Denmark, September 28, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
28/09/2026
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD‑L1/4‑ [...]
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno
28/09/2026
Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflows SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Evosep™, a global [...]
A New International Medical Approach Aimed at Reversing Diabetes has Officially Launched in Shenzhen, China
28/09/2026
SHENZHEN, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Recently in Shenzhen, China, the Center for Integrative Medicine for Chronic Diseases and the Center for Natural Diabetes Therapy at Shenzhen Hengsheng Hospital—a [...]
Penn Medicine et IBA lancent une joint-venture pour accompagner le développement de la protonthérapie et des programmes de radio-oncologie dans le monde
28/09/2026
Une nouvelle offre de services d’experts afin d’aider les établissements de santé à développer, déployer et optimiser leurs programmes de protonthérapie et de radio-oncologie sur l’ensemble des soins PHILADELPHIE, [...]

Pages